AlphAIAlphAI — Financial news for AI agents
biz.chosun.comOCT 52 min read$ADM

CJ CheilJedang partners with ADM to boost U.S. lysine output amid China curbs

CJ CheilJedang (097950) and ADM formed a joint venture to boost U.S. lysine production, with CJ holding a 63% stake. The move aims to compete with Chinese lysine amid tightened trade restrictions. CJ will contribute its U.S. and Brazil facilities, while ADM will provide its Illinois plant and raw material network. Lysine prices have rebounded due to trade actions against China, with U.S. prices up 38% since December.

Original reporting
biz.chosun.com
Published Oct 5, 2026, 5:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 9:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CJ CheilJedang partners with ADM to boost U.S. lysine output amid China curbs — source image
Source · biz.chosun.com
Decision brief

The 30-second read

$ADMBullishMed
01

Why it matters

The partnership positions ADM to capture higher lysine prices and diversify its feed‑ingredient portfolio.

02

Market read

A new JV in a tightening market could lift ADM's earnings outlook and affect lysine pricing globally.

03

What to watch

Regulatory approvals and integration risks could delay benefits.

Relevance 7/10Novelty 7/10Timing: today's announcement

Background

Chinese lysine exports have faced anti‑dumping duties, prompting U.S. firms to seek domestic sources.

Company-level read

Ticker impact

$ADMBullishHigh confidence
Context

ADM announced a joint venture with CJ CheilJedang to produce lysine in the U.S., marking a material partnership in the feed‑amino‑acid market.

Expected impact

likely upward pressure as the market prices in expanded U.S. lysine capacity and higher pricing.

Evidence & confidence

ADM gains a majority‑controlled production platform in a tightening market, supporting earnings outlook.

Market effects

Sector

U.S. feed‑amino‑acid sector may see tighter supply and higher prices, benefiting producers.

Regional

U.S. lysine market gains domestic capacity, reducing reliance on Chinese imports.

Global

Potential ripple effect on global livestock feed costs as U.S. prices rise.

Counterpoint

What could challenge this read

If trade restrictions ease, the JV could face overcapacity and margin pressure.

Key entities

  • company
    CJ CheilJedang

    Korean food and bio‑ingredients group forming the JV.

  • company
    Archer Daniels Midland (ADM)

    U.S. grain processor expanding into lysine production.

Read at source← All news

Related articles

OCT 3
$ADMMed

Amino Acids Venture Might Change The Case For Investing In ADM Stock

Archer-Daniels-Midland (ADM) and CJ CheilJedang formed a joint venture to produce and sell feed-grade amino acids in the Americas. The deal, with CJ as majority owner, includes ADM's Decatur facility. Analysts expect ADM's revenue to grow 2.8% annually to $89.2B by 2029, with earnings rising to $2.3B. The joint venture is part of ADM's broader strategy to focus on fermentation-based offerings and animal nutrition.

simplywall.st3 min
OCT 2
$ADMMedAI 8/10

CJ CheilJedang and ADM form amino acid joint venture

CJ CheilJedang (KRX:097950) and ADM (NYSE:ADM) agreed to form a joint venture to produce and market feed-grade amino acids in the Americas. CJ will license its technology and hold majority ownership. The venture will use facilities in Iowa, Illinois, and Brazil, aiming to enhance cost competitiveness and support U.S. production.

investing.com2 min
SEP 25
$ADMMed

ADM’s Infant Probiotic Trial: A New Data Catalyst In Consumer Health

Archer-Daniels-Midland (ADM) completed a clinical trial testing a probiotic for infant colic relief. The double-blinded, placebo-controlled study aims to support ADM's position in science-backed nutrition. Positive results could boost ADM's pediatric nutrition sales and stock sentiment. The trial was updated on September 22, 2026, with data analysis underway.

tipranks.com1 min
SEP 15
$CNCMed

2 Non-AI Giants to Buy on Solid Guidance and Lucrative Valuation

Centene Corp. (CNC) and Archer-Daniels-Midland Co. (ADM) are highlighted for strong performance and attractive valuations. CNC expects 2026 revenues of $173-$177B and adjusted EPS over $4.80, with a forward P/E of 13.58X. ADM raised 2026 adjusted earnings guidance to $5.15-$5.60 per share, with a forward P/E of 16.60X.

tradingview.com3 min
SEP 12
$ADMMedAI 8/10

SEC Produces 307,000 Documents in Fraud Case Against Former ADM CFO

The SEC has produced 307,000 documents in its fraud case against former ADM CFO Vikram Luthar, with ongoing document production. The case involves alleged inflation of ADM's Nutrition business performance. ADM settled related charges with a $40M penalty. Discovery is expected to continue until March 2027. Luthar is contesting the allegations in court.

the420.in2 min